We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

507 hedge funds and large institutions have $14.4B invested in Bio-Rad Laboratories Class A in 2021 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 171 increasing their positions, 198 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more call options, than puts

Call options by funds: $76.4M | Put options by funds: $54.5M

16% more capital invested

Capital invested by funds: $12.4B → $14.4B (+$2.01B)

11% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 44

0% more funds holding in top 10

Funds holding in top 10: 77 (0)

0.12% less ownership

Funds ownership: 78.65%78.53% (-0.12%)

0% less funds holding

Funds holding: 508507 (-1)

14% less repeat investments, than reductions

Existing positions increased: 171 | Existing positions reduced: 198

Holders
507
Holders Change
-1
Holders Change %
-0.2%
% of All Funds
8.88%
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.12%
New
49
Increased
171
Reduced
198
Closed
44
Calls
$76.4M
Puts
$54.5M
Net Calls
+$21.8M
Net Calls Change
+$60.4M
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
226
Ativo Capital Management
Illinois
$1.94M
WG
227
Winton Group
United Kingdom
$1.9M +$308K +411 +19%
MLICM
228
Metropolitan Life Insurance Company (MetLife)
New York
$1.85M -$68.2K -91 -4%
KAS
229
Kestra Advisory Services
Texas
$1.76M +$780K +1,041 +79%
SAM
230
Storebrand Asset Management
Norway
$1.76M -$617K -823 -26%
DT
231
Diversified Trust
Tennessee
$1.74M -$109K -145 -6%
PFM
232
Patton Fund Management
Texas
$1.73M -$28.5K -38 -2%
NAM
233
Nissay Asset Management
Japan
$1.73M +$71.2K +95 +4%
BCV
234
Banque Cantonale Vaudoise
Switzerland
$1.72M -$1.27M -1,700 -43%
RC
235
RegentAtlantic Capital
New Jersey
$1.71M -$153K -204 -8%
PAS
236
Park Avenue Securities
New York
$1.7M +$63.7K +85 +4%
AIA
237
Angeles Investment Advisors
California
$1.7M +$694K +926 +69%
Squarepoint
238
Squarepoint
New York
$1.69M -$3.94M -5,255 -70%
TPCW
239
TD Private Client Wealth
New York
$1.67M +$63.7K +85 +4%
YIH
240
Y-Intercept (HK)
Hong Kong
$1.66M +$1.66M +2,219 New
SC
241
SRB Corp
Massachusetts
$1.63M -$757K -1,011 -32%
EGM
242
Engineers Gate Manager
New York
$1.63M +$1.63M +2,180 New
VCM
243
Virtue Capital Management
Tennessee
$1.61M -$99.6K -133 -6%
Ensign Peak Advisors
244
Ensign Peak Advisors
Utah
$1.59M -$183K -244 -10%
VI
245
Versor Investments
New York
$1.58M -$35.2K -47 -2%
Jane Street
246
Jane Street
New York
$1.57M -$2.51M -3,357 -61%
AO
247
Advisor OS
Illinois
$1.56M -$68.9K -92 -4%
HIMCH
248
Hartford Investment Management Co (HIMCO)
Connecticut
$1.5M -$193K -257 -11%
Pacer Advisors
249
Pacer Advisors
Pennsylvania
$1.49M -$231K -309 -13%
SAM
250
Securian Asset Management
Minnesota
$1.47M

BIO Hedge Fund Activity: Q3 2021 in Review

507 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2021, worth a combined $14.4B — up 16% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new BIO positions and 44 closed out — a net gain of 5 holders — while 171 added to existing stakes and 198 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $244M. The largest seller was Deutsche Bank, cutting an estimated $75.2M.

  • 507 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2021, down from 508 in Q2 2021.
  • Funds reported $14.4B of Bio-Rad Laboratories Class A stock for Q3 2021, up 16% quarter-over-quarter.
  • 49 funds opened new Bio-Rad Laboratories Class A positions in Q3 2021 and 44 closed out, a net change of +5 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q3 2021 was Fidelity Investments, an estimated $244M added.
  • The largest Bio-Rad Laboratories Class A seller in Q3 2021 was Deutsche Bank, an estimated $75.2M sold.

Based on aggregated 13F filings for Q3 2021.